🔴 BioLineRx is trading 8.76% down in pre-market after Q2 revenue missed expectations and losses widened

BioLineRx is trading 8.76% down in pre-market at $2.50 as investors continue digesting its August 31, 2026 second-quarter results, which showed revenue below expectations and a widening net loss.

• Revenue was $0.3 million, net loss widened to $4.3 million, and APHEXDA royalty income remained limited.
• Management highlighted GLIX1 clinical progress and a $3.75 million financing, but no separate major September 3, 2026 announcement was identified; the decline appears tied primarily to earnings rather than broad market weakness.